Rationale: Atherosclerotic lesion formation is associated with the accumulation of oxidized lipids. Products of lipid oxidation, particularly aldehydes, stimulate cytokine production and enhance monocyte adhesion; however, their contribution to atherosclerotic lesion formation remains unclear. Objective: To test the hypothesis that inhibition of aldehyde removal by aldose reductase (AR), which metabolizes both free and phospholipid aldehydes, exacerbates atherosclerotic lesion formation. Methods and Results: In atherosclerotic lesions of apolipoprotein (apo)E-null mice, AR protein was located in macrophage-rich regions and its abundance increased with lesion progression. Treatment of apoE-null mice with AR inhibitors sorbinil or tolrestat increased early lesion formation but did not affect the formation of advanced lesions. Early lesions of AR ؊/؊ /apoE ؊/؊ mice maintained on high-fat diet were significantly larger when compared with age-matched AR ؉/؉ /apoE ؊/؊ mice. The increase in lesion area attributable to deletion of the AR gene was seen in both male and female mice. Pharmacological inhibition or genetic ablation of AR also increased the lesion formation in male mice made diabetic by streptozotocin treatment. Lesions in AR ؊/؊ /apoE ؊/؊ mice exhibited increased collagen and macrophage content and a decrease in smooth muscle cells. AR ؊/؊ /apoE ؊/؊ mice displayed a greater accumulation of the AR substrate 4-hydroxy trans-2-nonenal (HNE) in the plasma and protein-HNE adducts in arterial lesions than AR ؉/؉ /apoE ؊/؊ mice. Conclusions: These observations indicate that AR is upregulated in atherosclerotic lesions and it protects against early stages of atherogenesis by removing toxic aldehydes generated in oxidized lipids. (Circ Res. 2009;105:793-802.)
E xtensive evidence suggests that oxidation of lipoproteins that accumulate within the vessel wall is a significant feature of atherogenesis. In humans, the presence of oxidized lipids in the plasma and atherosclerotic lesions is strongly associated with coronary artery disease, acute coronary syndromes, and vulnerable plaques. 1, 2 In animal models, oxidized lipids have been detected in all stages of atherogenesis, and interventions that diminish lipid oxidation have been shown to decrease atherosclerotic lesion formation. Oxidizing lipids generate several bioactive molecules (eg, alkoxyl and peroxyl radicals, peroxides, and isoprostanes), of which aldehydes are the major end products. 3 These aldehydes are generated from free radical-mediated scission of bis-allylic double bonds in unsaturated fatty acids, and they remain esterified to the phosphoglycerol backbone or to cholesterol or they appear as free carbonyls of varying chain length. Among the free and the esterified aldehydes generated during lipid oxidation, the C-9 unsaturated aldehyde, 4-hydroxy trans-2-nonenal (HNE) and the C-5 esterified aldehyde 1-palmitoyl 2-oxovaleroyl phosphatidylcholine (POVPC) are the most abundant. 2 Protein adducts of HNE and POVPC have been detected in low-density lipoprotein (LDL) oxidized in vitro 4 and in atherosclerotic lesions of animals 5 and humans, 6 and positive reactivity of the plasma with anti-POVPC antibodies has been shown to correlate with lesion formation in apoE-null mice and with angiographically documented coronary artery disease in humans. 7 Aldehydes generated from oxidized lipids are highly reactive and they can increase monocyte adhesion, cytokine production, 7 and trigger autophagy. 8 Multiple biochemical pathways have been identified that metabolize these aldehydes, and these pathways could potentially prevent aldehyde toxicity by converting them into less reactive products. Previous studies have led to the identification of the important role of paraoxonase 9 and platelet-activating factor acyl hydrolase 2 in hydrolyzing oxidized sn-2 side chains of phospholipids and it has been shown that these enzymes protect against lesion development in atherosclerotic mice. 9 How-ever, in addition to paraoxonase and platelet-activating factor acyl hydrolase, lipid-derived aldehydes are also reduced by aldose reductase (AR). AR is a broad-specificity aldo-keto reductase, and it is an efficient catalyst for the reduction of a range of free aldehydes generated from oxidized lipids. The enzyme also catalyzes the reduction of glutathione conjugates of unsaturated lipid-derived aldehydes, 10 as well as POVPC and several related phospholipid aldehydes. 11 Nonetheless, the in vivo role of AR remains unclear. The present study was therefore designed to test the hypothesis that AR protects against atherosclerotic lesion formation by removing atherogenic lipidderived aldehydes. Our results show that inhibition or genetic ablation of AR accelerates atherosclerotic lesion formation in apoE-null mice. These findings support the concept that aldehydes generated by oxidized lipids contribute to atherogenesis and that AR protects against atherogenesis by removing lipid peroxidation-derived aldehydes.
Methods
The AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice were generated by breeding AR Ϫ/Ϫ mice with apoE Ϫ/Ϫ mice. Mice underwent the treatment protocols described in Figure 1 . Plasma lipids were measured using commercial kits. Sorbitol concentration in the kidney was measured spectrofluorometrically. Expression of cytokines in the spleen was measured by quantitative PCR and plasma interleukin-6 levels were measured by ELISA.
Concentrations of aldehydes in the plasma were measured by gas chromatography-mass spectrometry. Atherosclerotic lesion area was calculated using Metamorph 4.5 software. An expanded Methods section is available in the Online Data Supplement at http:/circres.ahajournals.org.
Results
To understand the role of AR in atherogenesis, we first examined the association of this protein with atherosclerotic lesions. For this, apoE-null mice fed standard chow were euthanized at 8 and 20 weeks of age. As shown in Figure 2A , in the innominate artery of 8-week-old mice, the expression of AR was mostly colocalized with that of CD31, suggesting that in nondiseased tissue the AR gene is expressed mostly in endothelial cells. In agreement with previous findings in rat 12, 13 and human 14 vessels, no immunoreactivity with anti-AR antibody was associated with the medial smooth muscle cells, suggesting that nonactivated smooth muscle cells do not express AR to the level observed in the endothelium. Lesions in the innominate artery of 20-week-old mice were intensely stained with anti-AR antibody ( Figure 2B ) and the expression of AR was colocalized with CD68 ϩ macrophages. The anti-AR antibody heavily stained the luminal surface of the lesion in the aortic sinus of 20-week-old apoE-null mice ( Figure 2C ). The expression of AR in the aortic sinus colocalized with that of MOMA-2, suggesting that the enzyme may be specifically associated with macrophages accumulating in the subintimal space. The abundance of AR increased with lesion progression (Online Figure I ). Intense staining with the anti-AR antibody was observed in the aortic sinus of 52-week-old mice and this staining colocalized with anti-MOMA-2 staining. These data demonstrate that although in nondiseased tissue the expression of AR is confined to the endothelium, the protein is abundant in the macrophage-rich regions of atherosclerotic lesions and its abundance increases with lesion progression.
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To examine the contribution of AR to atherogenesis, we studied how treatment with AR inhibitors would affect different stages of atherogenesis in apoE-null mice. For this, 8-week-old mice were maintained on a high-fat diet and fed 2 structurally different AR inhibitors: tolrestat or sorbinil for 4 weeks in drinking water (protocol I). At the end the study, the mice were euthanized and their plasma, kidney, heart, and aorta were harvested. Sorbitol content of the kidney was measured to ensure the dose efficacy of the AR inhibitors. In kidney, sorbitol is derived from AR-catalyzed reduction of glucose and tissue levels of sorbitol faithfully reflect cumulative AR activity. Our previous studies show that the changes in the levels of sorbitol in the aorta reflect those in the kidney. 15 Four weeks of treatment with either tolrestat or sorbinil decreased sorbitol content in the kidney by 70 to 85% (Online Figure II) . The extent of inhibition by the 2 drugs was similar, indicating that they were both equally effective in inhibiting AR in situ in apoE-null mice. Treatment with sorbinil or tolrestat, however, did not affect the plasma cholesterol and triglyceride concentrations (Online Table I or distribution of cholesterol in the lipoproteins [data not shown]). Treatment with sorbinil or tolrestat did not affect the body weight of the animals or their general health (data not shown). Based on these observations, we conclude that treatment with either tolrestat or sorbinil inhibits tissue AR activity but does not significantly affect plasma lipoprotein levels.
Morphometric analysis of the aortic roots showed that treatment with tolrestat led to a 1.9-fold increase in lesion formation when compared with vehicle-fed controls ( Figure  3A ). Staining of the aortic sinus with oil red O showed small lipid-laden foam cells in the cusps of the aortic valves of vehicle-fed controls. Accumulation of cholesterol-rich foam cells was significantly increased in aortic roots of tolrestatfed mice. Analysis of the aortic arch stained with Sudan IV showed a 2-fold increase in lesion area in tolrestat-fed mice versus vehicle-fed controls ( Figure 3B ). Similar results were obtained with sorbinil. Morphometric analysis of the aortic root lesions of sorbinil-fed mice showed that the lesion size was 2.2-fold higher in sorbinil-treated mice when compared with vehicle-fed controls ( Figure 3A ). An increase of similar magnitude was observed in lesions in the aortic arch ( Figure  3B ). No lesions were observed in the distal aorta of treated or untreated mice. Taken together, these data suggest that inhibition of AR accelerates early lesion formation in apoEnull mice.
We next examined whether inhibition of AR would affect lesion progression in the mice with preexisting lesions. For these experiments, mice were maintained on the standard chow diet till they were 24 weeks of age. At this age, these mice show intermediate lesions throughout the vasculature. The mice were then fed either sorbinil (protocol IIB) or vehicle II (protocol IIA) for 12 weeks and euthanized when they were 36 weeks of age. Sorbinil feeding did not affect plasma cholesterol and triglycerides (Online Table I ) in these mice. These mice developed advanced and complicated lesions; however, sorbinil treatment did not affect the extent of lesion formation either in the aortic root or in the abdominal aorta (Online Figure III) . These data suggest that inhibition of AR has no effect on the development of advanced lesions.
To further interrogate the role of AR in atherosclerotic lesion formation, we generated AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice. These mice were generated by breeding AR Ϫ/Ϫ mice (generated on Table I ). Western blot analysis of the heart homogenates confirmed the absence of AR protein in AR Ϫ/Ϫ / apoE Ϫ/Ϫ ( Figure 4A ). Morphometric analysis of the lesion area in the aortic sinus of the mice maintained on high-fat diet for 4 weeks showed that the mean lesion area of AR Ϫ/Ϫ / apoE Ϫ/Ϫ was 2.2-fold higher than that of the AR ϩ/ϩ /apoE Ϫ/Ϫ mice ( Figure 4B ; PϽ0.01). A similar increase in lesion area was observed in the aortic arch of AR Ϫ/Ϫ /apoE Ϫ/Ϫ when compared with AR ϩ/ϩ /apoE Ϫ/Ϫ mice ( Figure 4C ; PϽ0.01). At this age, no lesions were observed in the distal aorta of AR Ϫ/Ϫ /apoE Ϫ/Ϫ or AR ϩ/ϩ /apoE Ϫ/Ϫ mice (data not shown). These results, taken together with data obtained with AR inhibitors (Figure 3 ), suggest that AR protects against early lesion formation in apoE Ϫ/Ϫ mice.
To examine the role of AR in intermediate lesion formation, AR Ϫ/Ϫ /apoE Ϫ/Ϫ and AR ϩ/ϩ /apoE Ϫ/Ϫ mice, maintained on high-fat diet for 12 weeks (protocol IV), were used. Both male and female mice were used to identify gender-specific effects. Plasma cholesterol and triglyceride levels of AR Ϫ/Ϫ / apoE Ϫ/Ϫ mice were comparable with AR ϩ/ϩ /apoE Ϫ/Ϫ mice (Online Table I ). The lesion area in the aortic sinus, aortic arch, and abdominal aorta was 1.4-to 1.6-fold higher in the male AR Ϫ/Ϫ /apoE Ϫ/Ϫ than in male AR ϩ/ϩ /apoE Ϫ/Ϫ mice ( Figure 5A through 5C). When compared with male AR ϩ/ϩ / apoE Ϫ/Ϫ mice, mean lesion area in female AR ϩ/ϩ /apoE Ϫ/Ϫ mice was higher throughout the aortic tree. Lesion quantification in female AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice showed 1.6-to 1.9fold increase ( Figure 5D through 5F) higher lesion area in aortic valves, aortic arch, and the abdominal aorta, indicating that genetic ablation of AR enhances intermediate lesion formation and female AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice develop larger lesions than their male counterparts.
To examine lesion composition, sections of the aortic sinus of female AR Ϫ/Ϫ /apoE Ϫ/Ϫ and AR ϩ/ϩ /apoE Ϫ/Ϫ mice were stained with Sirius red for collagen, ␣-smooth muscle cell actin for smooth muscle cells, CD-3 for T lymphocytes, and MOMA-2 for macrophages. As shown in Figure 6A , the staining with Sirius red showed that the interstitial collagen content of the lesions of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice was 1.3-fold higher than AR ϩ/ϩ /apoE Ϫ/Ϫ mice (PϽ0.05). Staining for the smooth muscle cells showed that most of the smooth muscle cells were in the intimal area close to the lumen. The staining showed a 36% decrease in AR Ϫ/Ϫ /apoE Ϫ/Ϫ when compared with AR ϩ/ϩ /apoE Ϫ/Ϫ mice ( Figure 6B; PϽ0.02) . Only a few cells (Ͻ2%) showed positive staining for T lymphocytes. The extent of staining was similar in AR Ϫ/Ϫ /apoE Ϫ/Ϫ and AR ϩ/ϩ / apoE Ϫ/Ϫ mice (data not shown). The macrophage content (probed with anti MOMA-2 antibody), in AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice was 1.7-fold greater than the lesions of AR ϩ/ϩ /apoE Ϫ/Ϫ mice ( Figure 6C; PϽ0.01) . Similarly, a 1.4-fold increase in the number of CD68 ϩ macrophages in the aortic valves of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice was observed ( Figure 6D , i; PϽ0.02), however, there was no significant difference in the size of CD68 ϩ macrophages between the 2 groups ( Figure 6D , ii). The expression of cytokines in the spleens of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice was similar to AR ϩ/ϩ /apoE Ϫ/Ϫ mice (Online Figure IV,  A) . Plasma concentration of interleukin-6 of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice was also comparable to AR ϩ/ϩ /apoE Ϫ/Ϫ mice (Online Figure IV, B) . These observations suggest that genetic ablation of AR increases macrophage accumulation and interstitial fibrosis and decreases smooth muscle cell content of arterial lesions, without affecting systemic inflammation.
To examine whether the lack of AR prevents aldehyde removal, levels of the AR substrate HNE were measured in the plasma and protein-HNE adducts were quantified in arterial lesions. As shown in Figure 7A , anti-protein-HNE antibody showed sparse immunopositive reactivity within the aortic root lesions of AR ϩ/ϩ /apoE Ϫ/Ϫ mice. Confocal imaging showed weak staining with anti-protein-HNE antibody that was colocalized with the CD68 ϩ macrophages. The accumulation of protein-HNE adducts was markedly greater in the aortic roots of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice versus AR ϩ/ϩ / apoE Ϫ/Ϫ . A distinct increase in the protein-HNE staining was also observed in the innominate arteries of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice versus AR ϩ/ϩ /apoE Ϫ/Ϫ (Online Figure V, A) . Atherosclerotic lesions in innominate arteries also displayed marked immunoreactivity with another lipid peroxidation-derived aldehyde, malonaldialdehyde (MDA), which is not an AR substrate. No significant difference was observed in the protein-MDA staining in sections obtained from AR Ϫ/Ϫ / apoE Ϫ/Ϫ and AR ϩ/ϩ /apoE Ϫ/Ϫ lesions (Online Figure V, A) . Similar results were obtained with plasma. Figure 7B shows the chromatogram of the spectrum of PFB-oxime-TMS derivatives of HNE measured by GC-NICI-MS (gas chromatography-negative ionization chemical ionization/mass spectrometry) by select ion monitoring mode, in the plasma of AR ϩ/ϩ /apoE Ϫ/Ϫ and AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice ( Figure 7C ). D 11 -HNE was used as the internal standard. The following ions were monitored ( Figure 7C Figure 7D .
The plasma of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice showed 2.5-fold higher concentration of the AR substrate HNE than that of AR ϩ/ϩ /apoE Ϫ/Ϫ mice ( Figure 7B through 7D) . We also observed a significant increase in the plasma concentration of another AR substrate hexanal in AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice (data not shown). No difference in MDA levels was observed in the plasma of AR Ϫ/Ϫ /apoE Ϫ/Ϫ versus AR ϩ/ϩ /apoE Ϫ/Ϫ mice (Online Figure V) . These data suggest that in apoE-null mice deletion of the AR gene increases the accumulation of those aldehydes that are substrates of AR, without affecting the overall rate or extent of lipid peroxidation.
In addition to oxidized lipid-derived aldehydes, AR also catalyzes the metabolism of glucose. Therefore, we also examined the role of AR during atherogenesis in diabetic apoE-null mice. Diabetes was induced by streptozotocin and lesion formation was examined after 6 or 12 weeks of diabetes (protocol V). As shown in Figure 8 , in the diabetic mice, inhibition of AR by sorbinil increased the lesion formation by 1.6-fold ( Figure 8A ; PϽ0.02) in the aortic valve and 1.8 fold in the aortic arch (Online Figure VI) . Sorbinil feeding had no effect on plasma cholesterol and triglyceride concentrations (Online Table I ). Similar to pharmacological inhibition, genetic ablation of AR also increased lesion formation in diabetic mice. After 6 weeks of diabetes, the surface lesion area of AR Ϫ/Ϫ /apoE Ϫ/Ϫ mice was 1.6-fold larger in the aortic valve (PϽ0.02; Figure 8B ) and 1.7-fold larger in the aortic arch (PϽ0.02; Online Figure VI Figure  VI, B) . These data suggest that as in nondiabetic mice, inhibition of AR increases atherogenesis in diabetic apoEnull mice.
Discussion
The major finding of this study is that inhibition of AR exacerbates atherosclerotic lesion formation in nondiabetic and diabetic apoE-null mice. This finding supports the concept that aldehydes generated by lipid peroxidation promote atherogenesis and that the processes involved in detoxifying these aldehydes may be significant modulators of atherogenesis. The observation that inhibition of AR increases and accelerates the formation of early and intermediate lesions but does not affect the progression of preformed plaques indicates that aldehyde metabolism by AR may be particularly significant during the early stages of lesion formation. Acceleration of atherogenesis in mice treated with AR inhibitors was not associated with significant changes in plasma lipoprotein levels but with an increase in the accumulation of protein-HNE adducts within the aortic lesions, suggesting that inhibition by AR does not ameliorate systemic dyslipidemia but rather promotes the accumulation of lipid peroxidation-derived aldehydes within the vessel wall. Extensive evidence supports the concept that AR is a critical participant in the metabolism and detoxification of aldehydes derived from lipid peroxidation. The catalytic cycle, the active site, and the energetics of the enzyme are optimized for the removal of variety of endogenous aldehydes ranging from saturated and unsaturated aldehydes, phospholipid aldehydes, steroid aldehydes, 2-oxo-aldehydes, and base propenals. 16 Because most of these aldehydes are highly reactive and are generated endogenously during oxidative stress, their reduction by AR could be considered to be an antioxidant defense mechanism. Consistent with this role, AR has been found to be increased by oxidative stress induced by hydrogen peroxide, HNE, NO, methylglyoxal, or iron overload. 16 The levels of AR are also elevated during oxidative stress in vivo in myocardial ischemia-reperfusion, 17 restenosis, 12 vasculitis, 14 and atherogenesis (this study; Figure  2 ). Moreover, it has been recently shown that the AR gene is transcriptionally upregulated by the binding of Nrf2 to the antioxidant response element at the 5Ј-flanking region of the AR gene 18 and that during myocardial ischemia AR is activated by post-translational modification of its cysteine residues to sulfenic acid. 19 Transcriptional and posttranslational increases during oxidative stress indicate that AR may be an important component of the antioxidant response specifically upregulated to prevent aldehyde toxicity. This role of AR is in agreement with previous reports showing that inhibition of AR increases the toxicity of aldehydes such as HNE, 20 acrolein, and glycoaldehyde 21 and promotes aldehyde accumulation in inflamed arteries 14 and the ischemic heart. 17 Thus, elevated levels of AR seen in atherosclerotic lesions in the present study support the idea that the accumulation of lipid peroxidation products is a significant cause of oxidative stress in atherosclerotic lesions and that AR prevents lesion formation by mitigating their toxicity. Significantly, we found that deletion of AR increased the levels of HNE and hexanal in the plasma and the protein-HNE in the lesions, without affecting plasma MDA levels or the abundance of protein-MDA adducts in the lesions. These observations suggest that loss of AR does not lead to a systemic increase in lipid peroxidation or oxidative stress (because levels of MDA were not affected) but that it prevents the removal of only those aldehydes that are AR substrates (ie, HNE and hexanal). Accumulation of oxidized lipids in the subintimal space is believed to be an initiating event in atherogenesis. 2 Although LDL in its native form is not atherogenic, oxidation in the acellular regions of the vessel wall transforms the particle into an inflammatory trigger and a high-affinity ligand of the scavenger receptor. In support of this view, it has been shown that oxidized LDL induces the synthesis of cytokines and chemokines such as monocyte chemoattractant protein-1 and interleukin-8 and that it could recruit inflammatory cells to the lesion by promoting endothelial-monocyte adhesion. 1, 2 Several of the atherogenic properties of oxidized LDL have been linked to the generation of lipid peroxidation-derived aldehydes such as HNE and POVPC, 1,2 which are substrates of AR. Hence reduction by AR, which coverts the reactive aldehyde function to an alcohol could reduce toxicity and thereby prevent the activation of the processes by which aldehydes generated in oxidized LDL contribute to lesion progression. In agreement with the view that reduction decreases the bioactivity of lipid-derived aldehydes, it has been shown that chemical reduction of POVPC abolishes its ability to promote the binding of monocytes to the endothe-lium, 22 suggesting that the metabolic transformation by AR could decrease the bioactivity as well as the atherogenic effects of lipid-derived aldehydes.
The notion that AR is a major determinant of aldehyde metabolism in vascular lesions is consistent with our observation that inhibition of AR increases the accumulation of protein-aldehyde adducts in the lesion and accelerates the formation of early and intermediate lesions. Nevertheless, the possibility that alcohol products of lipid peroxidation could retain or enhance the biological activity of the aldehydes could not be ruled out. Indeed, our studies show that in smooth muscle cells, AR is essential for the activation of nuclear factor (NF)-B by growth factors and cytokines 16, 23 and that reduction of glutathionyl-HNE by AR is an activating step in HNE metabolism which is required for NF-B activation and for stimulation of smooth muscle cell growth. 24 The mechanisms that impart a dual role to AR are unclear, but it appears likely that the pro-and antiinflammatory roles of AR depend on the metabolic context. A similar duality of function is associated with NF-B, which is regulated by AR. 23 Activated NF-B has been detected in macrophages, smooth muscle cells, and endothelial cells of atherosclerotic lesions and lesion prone sites 25 ; however, inhibition of NF-B in macrophage increases atherosclerosis and lesion inflammation. 26 Thus, reduction of aldehydes and their glutathione conjugates by AR could be beneficial under some conditions but not others. Indeed, the complex role of AR is highlighted by the contrast between the findings of our present study and those of Vikramadithyan et al, who reported that general transgenic overexpression of AR driven by a mouse histocompatibility antigen class I promoter increased the formation of atherosclerotic lesions in streptozotocin-treated diabetic LDL receptor-null mice without affecting lesion formation in nondiabetic mice. 27 In contrast, our results show that genetic ablation or pharmacological inhibition of AR increases lesion formation in both diabetic and nondiabetic mice. It is possible that the expression of the AR transgenic in tissues, where AR is not basally expressed (for example, vascular smooth muscle cells and liver) could artificially affect lesion formation by inducing nonspecific changes in other genes caused by constitutive overexpression of AR. Our results (Figure 2) show that AR is mostly associated with atherosclerotic lesions and thus a basal level of expression of AR in tissues where it is not expressed (eg, smooth muscle cells) could artificially promote lesion formation (AR is a critical regulator of vascular smooth muscle cells and neointima formation). 12, 13 In this regard, our data showing similar effects caused by a loss of AR catalysis during lesion formation (by pharmacological inhibition) or constitutive deletion of the AR gene both in diabetic and nondiabetic mice provide consistent evidence that AR prevents the formation of early and intermediate lesions. This is important because AR inhibitors have been suggested to be potential therapeutic agents for the treatment of secondary diabetic complications. 16 Our finding that inhibition of aldehyde metabolism promotes atherosclerotic lesions formation provides further support to the concept that lipoprotein oxidation is a critical regulator of atherogenesis. Although, oxidized lipids and their electrophilic components have been shown to induce a variety of atherogenic effects in cell culture systems, direct in vivo evidence implicating their involvement in lesion formation is lacking. Hence, our studies showing that inhibition of metabolism and detoxification of at least one component of oxidized lipids aggravates lesion formation provides the first line of evidence that in addition to being foot prints of oxidative stress, aldehydes derived from lipid peroxidation play a direct role in atherosclerosis. Results of lesion analysis show loss of AR is associated with an increase in collagen deposition and a decrease in smooth muscle cell content. This is surprising because collagen deposition in plaques and the formation of a fibrous cap have been linked to smooth muscle cells in the lesion. However, our previous work shows that AR is essential for smooth muscle cell growth in culture 12 and that inhibition of AR prevents neointima formation in injured arteries. 13 However, the loss of AR, which results in the accumulation of its substrate HNE in the lesion could increase profibrogenic activity. 28 It has been shown that HNE induces transforming growth factor ␤1 and activates activator protein-1, thereby increasing collagen synthesis. 29 The observation that inhibition of AR prevents the formation of early and intermediate lesions agrees with the present view of the role of oxidative stress in atherosclerosis. Recruitment of monocytes and the formation of foam cells are early events that are most likely triggered by oxidized components of LDL, whereas during later stages of lesion formation, the production of cytokines and inflammatory circuits within the vessels may be self-sustaining. The insensitivity of late lesion to AR inhibition is consistent with this view and suggests that lipid peroxidation products differentially play a more important role during the early than during the advanced stages of plaque generation.
In summary, we have found that inhibition of AR exacerbates atherosclerotic lesion formation and promotes vascular accumulation of protein-aldehyde adducts in apoE-null mice without affecting plasma lipoproteins. These observations support the concept that aldehydes derived from lipid peroxidation play a central and causal role in the formation and the progression of aortic lesions and that processes that decrease the accumulation and the toxicity of lipid-derived aldehydes may be beneficial in preventing or diminishing plaque burden. On one hand, the observations reported here highlight the need for additional mechanistic studies to delineate the role of aldehyde metabolism in regulating vascular inflammation, cholesterol uptake, and lesion formation; on the other hand, the observations highlight the necessity of additional molecular epidemiological studies to assess whether interindividual or polymorphic changes in the genes for AR (or other aldehyde-metabolizing enzymes) regulate the overall risk of cardiovascular disease in human populations.
